Julien Mazières
About
Julien Mazières is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Julien Mazières has authored 441 papers receiving a total of 17.0k indexed citations (citations by other indexed papers that have themselves been cited), including 313 papers in Pulmonary and Respiratory Medicine, 286 papers in Oncology and 79 papers in Molecular Biology. Recurrent topics in Julien Mazières's work include Lung Cancer Treatments and Mutations (241 papers), Lung Cancer Research Studies (108 papers) and Cancer Immunotherapy and Biomarkers (95 papers). Julien Mazières is often cited by papers focused on Lung Cancer Treatments and Mutations (241 papers), Lung Cancer Research Studies (108 papers) and Cancer Immunotherapy and Biomarkers (95 papers). Julien Mazières collaborates with scholars based in France, United States and Spain. Julien Mazières's co-authors include Benjamin Besse, David M. Jablons, Biao He, Zhidong Xu, Liang You, David Planchard, Fabrice Barlési, Nicolas Guibert, Anne Pradines and Bruce E. Johnson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.
In The Last Decade
Julien Mazières
411 papers receiving 16.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Julien Mazières France | 59 | 10.7k | 9.7k | 5.7k | 3.0k | 1.5k | 441 | 17.0k | ||
| David Planchard France | 58 | 11.0k 1.0× | 10.0k 1.0× | 4.6k 0.8× | 3.4k 1.1× | 1.1k 0.7× | 431 | 16.5k | ||
| Benjamin Besse France | 64 | 12.2k 1.1× | 10.4k 1.1× | 5.6k 1.0× | 3.8k 1.2× | 2.2k 1.5× | 708 | 18.8k | ||
| Lynette M. Sholl United States | 63 | 6.9k 0.6× | 6.8k 0.7× | 4.6k 0.8× | 3.1k 1.0× | 1.5k 1.0× | 310 | 14.5k | ||
| Benjamin Solomon Australia | 61 | 12.7k 1.2× | 14.1k 1.5× | 6.7k 1.2× | 4.3k 1.4× | 1.1k 0.7× | 415 | 20.8k | ||
| Byoung Chul Cho South Korea | 70 | 13.2k 1.2× | 12.9k 1.3× | 5.7k 1.0× | 3.2k 1.1× | 2.0k 1.3× | 689 | 19.8k | ||
| Ji‐Youn Han South Korea | 49 | 9.6k 0.9× | 8.2k 0.8× | 3.1k 0.5× | 2.1k 0.7× | 1.3k 0.9× | 257 | 13.1k | ||
| David R. Spigel United States | 68 | 14.4k 1.3× | 9.9k 1.0× | 5.0k 0.9× | 2.9k 1.0× | 1.7k 1.2× | 611 | 20.0k | ||
| Stefan Sleijfer Netherlands | 61 | 7.1k 0.7× | 4.7k 0.5× | 4.2k 0.7× | 3.5k 1.2× | 1.5k 1.0× | 379 | 13.6k | ||
| Vassiliki A. Papadimitrakopoulou United States | 57 | 7.7k 0.7× | 7.4k 0.8× | 4.1k 0.7× | 2.7k 0.9× | 1.0k 0.7× | 223 | 12.7k | ||
| Balázs Halmos United States | 48 | 8.0k 0.7× | 7.6k 0.8× | 4.9k 0.9× | 2.2k 0.7× | 733 0.5× | 280 | 12.7k |
Countries citing papers authored by Julien Mazières
Since
Specialization
Citations
This map shows the geographic impact of Julien Mazières's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julien Mazières with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julien Mazières more than expected).
Fields of papers citing papers by Julien Mazières
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Julien Mazières. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julien Mazières. The network helps show where Julien Mazières may publish in the future.
Co-authorship network of co-authors of Julien Mazières
This figure shows the co-authorship network connecting the top 25 collaborators of Julien Mazières. A scholar is included among the top collaborators of Julien Mazières based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julien Mazières. Julien Mazières is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Denis, Marc G., et al.. (2024). Résistance aux anti-EGFR via l’acquisition successive et cumulée de deux nouvelles addictions oncogénique BRAF et ALK. Revue des Maladies Respiratoires. 41(6). 451–454.
2.
Garinet, Simon, Caroline Léger, Fabrice Barlési, et al.. (2024). STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial. Lung Cancer. 190. 107508–107508.
3.
Reinmuth, Niels, Julien Mazières, Sanjay Popat, et al.. (2024). Health-related quality of life (HRQoL) with tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) with brain, liver, adrenal, or bone metastases in the phase II VISION trial.. Journal of Clinical Oncology. 42(16_suppl). 8575–8575.
4.
Solomon, Benjamin, Geoffrey Liu, Enriqueta Felip, et al.. (2024). Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. Journal of Clinical Oncology. 42(29). 3400–3409.
5.
Chaltiel, Léonor, Carole Massabeau, Audrey Rabeau, et al.. (2023). Impact of radiation on host immune system in patients treated with chemoradiotherapy and durvalumab consolidation for unresectable locally advanced non-small cell lung cancer. Frontiers in Oncology. 13. 1186479–1186479.
6.
Dall’Olio, Filippo Gustavo, Damien Vasseur, Maryam Karimi, et al.. (2023). Association of ctDNA tumor fraction with survival in advanced non-small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial.. Journal of Clinical Oncology. 41(16_suppl). 2516–2516.
7.
Le, Xiuning, Anna Eisert, Te‐Chun Hsia, et al.. (2023). Patients with EGFR mutant (m) MET-altered NSCLC receiving tepotinib with an EGFR tyrosine kinase inhibitor (TKI): A case series.. Journal of Clinical Oncology. 41(16_suppl). 9070–9070.
8.
Taillé, Camille, Grégoire Prévôt, A. Didier, et al.. (2022). De-labelling severe asthma diagnosis: the challenge of DIPNECH. ERJ Open Research. 8(1). 485–2021.
9.
Lavolé, A., Julien Mazières, S. Schneider, et al.. (2021). Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial. Lung Cancer. 158. 146–150.
10.
Wislez, Marie, Charlotte Domblides, Laurent Greillier, et al.. (2021). Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA). Lung Cancer. 157. 124–130.
11.
Bergoglio, Valérie, Yea‐Lih Lin, Marie‐Jeanne Pillaire, et al.. (2019). Overexpression of Claspin and Timeless protects cancer cells from replication stress in a checkpoint-independent manner. Nature Communications. 10(1). 910–910.
12.
Eberst, Guillaume, Amélie Anota, Arnaud Scherpereel, et al.. (2019). Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial. Clinical Cancer Research. 25(19). 5759–5765.
13.
Vendrell, Julie A., Julien Mazières, Isabelle Rouquette, et al.. (2019). Ultra-sensitive EGFR T790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring EGFR del19 Mutations and Treated with First-generation TKIs. Clinical Cancer Research. 25(14). 4280–4289.
14.
Dubois, Fatéméh, Maureen Keller, Olivier Calvayrac, et al.. (2016). RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non–Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway. Cancer Research. 76(6). 1627–1640.
15.
Ramalingam, Suresh S., Normand Blais, Julien Mazières, et al.. (2016). Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research. 23(8). 1937–1944.
16.
Fallet, Vincent, Raphaël Saffroy, Nicolas Girard, et al.. (2015). High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets. Annals of Oncology. 26(8). 1748–1753.
17.
Moro‐Sibilot, Denis, Clarisse Audigier-Valette, P. Merle, et al.. (2015). Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study). Lung Cancer. 89(2). 139–145.
18.
Calvayrac, Olivier, Anne Pradines, Isabelle Raymond‐Letron, et al.. (2014). RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer. Clinical Cancer Research. 20(24). 6541–6550.
19.
Laffaire, Julien, Paul Hofman, Michèle Beau‐Faller, et al.. (2012). A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma. Clinical Cancer Research. 18(20). 5606–5616.
20.
Bousquet, Emilie, Julien Mazières, Maud Privat, et al.. (2009). Loss of RhoB Expression Promotes Migration and Invasion of Human Bronchial Cells Via Activation of AKT1. Cancer Research. 69(15). 6092–6099.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by David Planchard Breakdown of academic impact, for papers by Benjamin Besse Breakdown of academic impact, for papers by Lynette M. Sholl Breakdown of academic impact, for papers by Benjamin Solomon Breakdown of academic impact, for papers by Byoung Chul Cho Breakdown of academic impact, for papers by Ji‐Youn Han Breakdown of academic impact, for papers by David R. Spigel Breakdown of academic impact, for papers by Stefan Sleijfer Breakdown of academic impact, for papers by Vassiliki A. Papadimitrakopoulou Breakdown of academic impact, for papers by Balázs Halmos